Hyderabad is fast emerging as a major centre for international pharmaceutical and healthcare businesses. After Medtronic announced that it would locate its global capacity center (GCC) in Hyderabad, Sanofi, a pharmaceutical company located in Paris, said that it would invest €400 million, or around ₹3,600 crore, in its Hyderabad GCC by 2030. By 2025, ₹900 crore, or over €100 million, of this investment will have been invested. Hyderabad is the largest of Sanofi’s four global centers, with roughly 1,000 employees at the moment. Within the next two years, the company hopes to grow this number to about 2,600.
The importance of this development was emphasized by IT and Industries Minister D. Sridhar Babu at the opening of Sanofi Healthcare India’s expanded GCC facility at Hitec City. He pointed out that Telangana’s increasing prominence in the global pharmaceutical scene is reflected in the sizeable investment and the creation of over 2,600 employment. This action is in line with the state’s goal to creating an atmosphere that encourages growth and innovation.
Like its other global hubs, Sanofi’s Hyderabad GCC will function as a strategic hub to give it a competitive edge in offering enterprise solutions. In order to modernize and centralize operations and enable scalability throughout Sanofi’s value chain, this center is crucial. Services including supply, R&D, digital solutions, and manufacturing and commerce will all be provided. The Hyderabad hub was first established in 2019 as a medical center, but it has since developed into a full service provider for Sanofi’s affiliates and global activities.
The city’s vast skill pool is the reason it has become a sought-after location for shared services. The executive vice president of business operations at Sanofi, Madeleine Roach, showed enthusiasm in making investments in Hyderabad. She highlighted how the center is redefining operational procedures and increasing efficiency, with digitization serving as the foundation for Sanofi’s transformation. The goal of this effort is to create a strong, international community that values excellence.
Sanofi wants to be the first biopharmaceutical company to use artificial intelligence (AI) on a large scale. Executive vice president and chief digital officer of Sanofi, Emmanuel Frenehard, emphasized the responsible and moral application of AI from medicine discovery to treatment. Sanofi hopes to expedite the release of medications to address unmet medical needs by utilizing AI.
To sum up, Sanofi’s substantial investment in Hyderabad highlights the city’s increasing significance as a global center for pharmaceuticals. The expansion puts Sanofi at the forefront of the biopharmaceutical sector and signals a strategy shift towards healthcare innovation and digitization in addition to the creation of jobs and economic prosperity.
SOURCE:
MEDICAL DIALOGUES
